StockNews.com Initiates Coverage on Catalent (NYSE:CTLT)

Research analysts at StockNews.com assumed coverage on shares of Catalent (NYSE:CTLT) in a note issued to investors on Monday. The firm set a “hold” rating on the stock.

A number of other equities analysts have also commented on CTLT. Robert W. Baird reiterated a “neutral” rating and issued a $63.50 price objective on shares of Catalent in a research note on Tuesday, September 24th. Baird R W lowered shares of Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Eight investment analysts have rated the stock with a hold rating, According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $63.40.

Catalent Stock Performance

Shares of CTLT opened at $63.48 on Monday. The firm has a market cap of $11.52 billion, a price-to-earnings ratio of -28.09, a price-to-earnings-growth ratio of 2.69 and a beta of 1.15. Catalent has a 12 month low of $41.15 and a 12 month high of $63.50. The company’s fifty day moving average is $62.24 and its 200-day moving average is $60.47. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same period in the prior year, the business earned ($0.10) EPS. The company’s revenue for the quarter was up 4.2% compared to the same quarter last year. Equities analysts expect that Catalent will post 0.78 EPS for the current fiscal year.

Insider Activity

In other news, Director Michelle R. Ryan sold 2,800 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the sale, the director now directly owns 10,835 shares in the company, valued at approximately $646,849.50. This trade represents a 20.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 0.31% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Catalent

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Sumitomo Mitsui DS Asset Management Company Ltd increased its holdings in shares of Catalent by 1.1% in the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,458 shares of the company’s stock valued at $1,179,000 after purchasing an additional 220 shares in the last quarter. Crossmark Global Holdings Inc. boosted its stake in Catalent by 2.6% in the third quarter. Crossmark Global Holdings Inc. now owns 9,133 shares of the company’s stock valued at $553,000 after acquiring an additional 229 shares during the last quarter. Vanguard Personalized Indexing Management LLC lifted its stake in Catalent by 3.8% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 7,688 shares of the company’s stock valued at $432,000 after buying an additional 278 shares during the period. GAMMA Investing LLC lifted its holdings in Catalent by 26.9% during the third quarter. GAMMA Investing LLC now owns 1,310 shares of the company’s stock worth $79,000 after acquiring an additional 278 shares in the last quarter. Finally, Greenleaf Trust lifted its holdings in shares of Catalent by 10.7% during the 3rd quarter. Greenleaf Trust now owns 4,294 shares of the company’s stock valued at $260,000 after purchasing an additional 416 shares in the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.